Expert Interview
Discussing the data presented at the CTAD conference for Lilly's Donanemab from the TRAILBLAZER-ALZ 2 study in Early Symptomatic Alzheimer’s Disease
Ticker(s): LLYInstitution: Neurology Center of Lumberton
- board-certified in Neurology and Sleep Medicine
- expertise in diagnosing & treating Alzheimer's disease, Vascular dementia, Diffuse Lewy body dementia, Guillain-Barre syndrome and CIDP(chronic inflammatory demyelinating polyneuropathy),
- manages treatment for 36 patients with CIDP and 120 patients with Alzheimer's Disease
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
